Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis : Case report and literature review

• Published in: Dermatology (Basel) Vol. 215; no. 3; pp. 245 - 251
• Main Authors: JUILLERAT, Pascal, CHRISTEN-ZÄCH, Stephanie, TROILLET, Francois-Xavier, GALLOT-LAVALLEE, Suzanne, PANNIZZON, Renato G, MICHETTI, Pierre
• Format: Journal Article
• Language: English
• Published: Basel Karger 01.09.2007; S. Karger AG
• Subjects: Adult; Antibodies, Monoclonal - therapeutic use; Biological and medical sciences; Case studies; Clinical outcomes; Colitis, Ulcerative - complications; Dermatologic Agents - therapeutic use; Dermatology; Drug therapy; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Inflammatory bowel disease; Infliximab; Medical sciences; Other diseases. Semiology; Pyoderma Gangrenosum - drug therapy; Pyoderma Gangrenosum - etiology; Skin diseases; Skin involvement in other diseases. Miscellaneous. General aspects; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Skin disease; Dermatology; Cytokine; Crohn's disease; Monoclonal antibody; Inflammatory disease; Case study; Immunomodulator; Crohn disease; Association; Treatment; Neutrophilic dermatosis; Infliximab; Anticytokine; Digestive diseases; Intestinal disease; Disseminated; Immunosuppressive agent; Tumor necrosis factor α; Pyoderma gangrenosum; Ulcerative colitis
• ISSN: 1018-8665; 1421-9832
• DOI: 10.1159/000106584

We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-alpha antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn's-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.